Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tango Therapeutics Inc (NQ: TNGX )

3.800 -0.120 (-3.06%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,255,381
Open 3.940
Bid (Size) 3.750 (5)
Ask (Size) 4.040 (82)
Prev. Close 3.920
Today's Range 3.760 - 4.150
52wk Range 2.700 - 13.01
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Analyst Landscape: 5 Takes On Tango Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga

Performance

YTD
-61.92%
-61.92%
1 Month
-35.81%
-35.81%
3 Month
-68.15%
-68.15%
6 Month
-44.53%
-44.53%
1 Year
-49.67%
-49.67%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
From Tango Therapeutics, Inc.
Via Business Wire
Analyst Scoreboard: 4 Ratings For Tango Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Tango Therapeutics to Participate in Upcoming Investor Conferences
From Tango Therapeutics, Inc.
Via Business Wire
Analyst Expectations For Tango Therapeutics's Future
Via Benzinga
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
Expert Outlook: Tango Therapeutics Through The Eyes Of 6 Analysts
Via Benzinga
Forecasting The Future: 4 Analyst Projections For Tango Therapeutics
Via Benzinga
Recap: Tango Therapeutics Q4 Earnings
Via Benzinga
Tango Therapeutics: Q3 Earnings Insights
Via Benzinga
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Tango Therapeutics, Inc.
Via Business Wire
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Tango Therapeutics Announces Discontinuation of TNG348 Program
From Tango Therapeutics
Via Business Wire
TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics, Inc.
Via Business Wire
TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
Tango Therapeutics to Participate in Upcoming Investor Conferences
From Tango Therapeutics, Inc.
Via Business Wire
Pancreatic Cancer Treatments Poised for Major Advances in 2024
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.